Suppr超能文献

经导管瓣环植入术治疗外科修复后残余或复发三尖瓣功能障碍。

Transcatheter Valve-in-Ring Implantation for the Treatment of Residual or Recurrent Tricuspid Valve Dysfunction After Prior Surgical Repair.

机构信息

Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Mayo Clinic, Rochester, Minnesota.

出版信息

JACC Cardiovasc Interv. 2017 Jan 9;10(1):53-63. doi: 10.1016/j.jcin.2016.10.036.

Abstract

OBJECTIVES

This study sought to describe the results of transcatheter tricuspid valve-in-ring (TVIR) implantation for treatment of tricuspid regurgitation (TR).

BACKGROUND

Off-label use of transcatheter valves within surgically placed tricuspid annuloplasty prostheses has only been described in small reports. An international multicenter registry was developed to collect data on TVIR implantation.

METHODS

Data were collected from 13 sites on 22 patients (5 to 69 years of age) with TR who underwent catheterization with the intent to perform TVIR implantation.

RESULTS

TVIR implantation was performed in 20 patients (91%). Most patients were severely impaired (86% in New York Heart Association functional class III or IV); TR was severe in 86%. A Sapien valve (Edwards Lifesciences, Irvine, California) was implanted in 17 patients and a Melody valve (Medtronic, Minneapolis, Minnesota) in 3. There were no procedural deaths. There was 1 valve embolization requiring retrieval and placement of second TVIR implant and 1 valve malposition with severe paravalvular regurgitation requiring a second TVIR implantation. Over a median follow-up of 12 months, 1 patient died and 2 underwent repeat TVIR implantation, 1 of whom subsequently underwent surgical valve replacement. Significant paravalvular leak (PVL) was treated at the time of TVIR implantation in 4 patients: 3 underwent device occlusion and 1 received a second TVIR implant. On follow-up echocardiography, 15 patients had PVL (75%), the majority of which (n = 10) were trivial or mild and did not require treatment. PVL intervention was performed in 3 patients during follow-up. Functional capacity improved in most patients (70%).

CONCLUSIONS

TVIR implantation using commercially available transcatheter prostheses is technically feasible and clinically effective in reducing TR. Paravalvular regurgitation is common and may necessitate further interventions.

摘要

目的

本研究旨在描述经导管三尖瓣环内(TVIR)植入术治疗三尖瓣反流(TR)的结果。

背景

经导管瓣膜在外科放置的三尖瓣瓣环成形环假体中的应用仅在小报告中有所描述。为了收集 TVIR 植入的数据,建立了一个国际多中心登记处。

方法

从 13 个地点的 22 名(年龄 5 至 69 岁)TR 患者收集数据,这些患者接受了经导管治疗,目的是进行 TVIR 植入。

结果

20 名患者(91%)进行了 TVIR 植入。大多数患者功能严重受损(86%在纽约心脏协会功能分级 III 或 IV);TR 严重的占 86%。17 例植入了 Sapien 瓣膜(爱德华兹生命科学公司,加利福尼亚州欧文),3 例植入了 Melody 瓣膜(美敦力公司,明尼苏达州明尼阿波利斯)。无手术死亡。有 1 例瓣膜栓塞需要取出并植入第二个 TVIR 植入物,1 例瓣膜位置不良伴严重瓣周反流需要植入第二个 TVIR 植入物。在中位随访 12 个月期间,1 例患者死亡,2 例患者接受了重复 TVIR 植入,其中 1 例随后接受了外科瓣膜置换术。4 名患者在 TVIR 植入时接受了治疗:3 名患者接受了器械闭塞,1 名患者接受了第二次 TVIR 植入。在随后的超声心动图检查中,15 名患者存在瓣周漏(PVL)(75%),其中大多数(n=10)为轻微或轻度,无需治疗。在随访期间,3 名患者进行了 PVL 干预。大多数患者的功能能力得到改善(70%)。

结论

使用商业上可获得的经导管假体进行 TVIR 植入在技术上是可行的,并且在降低 TR 方面具有临床效果。瓣周反流很常见,可能需要进一步干预。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验